References

* 1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. 2nd edn. Cephalalgia. 2004; 24: 1-150.

2. Russell M, Rasmussen BK, Brennum J etal. Presentation of a new instrument. The diagnostic headache diary. Cephalalgia. 1992; 12: 369-74.

3. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. Journal of Clinical Epidemiology. 1991; 44: 1147-57.

4. Gobel H, Petersen-Braun M, Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the Headache Classification of the International Headache Society. Cephalalgia. 1994; 14: 97-106.

5. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of subtypes of migraine. International Journal of Epidemiology. 1995; 24: 612-18.

6. Rasmussen BK, Stewart WF. Epidemiology of migraine. In Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 227-33.

7. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998; 279: 381-3.

8. Iversen HK, Langemark M, Andersson PG et al. Clinical characteristics of migraine and tension-type headache in relation to new and old diagnostic criteria. Headache. 1990; 30: 514-19.

* 9. Goadsby P, Tfelt-Hansen P. Cluster headache:

introduction and epidemiology. In: Olesen J, Tfelt-Hansen P, Goadsby PJ etal. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 743-5.

10. Rasmussen BK. Migraine and tension-type headache in a general population: Precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993; 53: 65-72.

11. Kudrow L. Muscle contraction headaches. In: Clifford Rose F (ed.). Handbook of clinical neurology. Headache. Amsterdam: Elsevier Science, 1986. 4: 343-52.

12. Langemark M, Olesen J, Poulsen DL, Bech P. Clinical characterization of patients with chronic tension headache. Headache. 1988; 28: 590-6.

13. Rasmussen BK. Migraine and TTH in a general population: psychosocial factors. International Journal of Epidemiology. 1992; 21: 1138-43.

14. Olesen J. Clinical characterization of tension headache. In: Olesen J, Edvinsson L (eds). Basic mechanisms of headache. Amsterdam: Elsevier Science, 1988: 9-14.

15. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology. 2005; 65: 580-5.

* 16. Olesen J, Goadsby PJ, Ramadan N et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott, Williams Ö Wilkins, 2006.

17. Ophoff RA, Terwindt GM, Vergouwe MN et al. Familial hemiplegic migraine and epidodic ataxia type-2 are caused by mutations in the Ca21 channel gene CACNL1A4. Cell. 1996; 87: 543-52.

18. Terwindt GM, Ophoff RA, Haan J et al. Migraine, ataxia and epilepsy: a challenging spectrum of genetic determined calcium channelopathies. European Journal of Human Genetics. 1998; 6: 297-307.

19. Ferrari MD, Haan J, Palotie A. Genetic of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 251-68.

20. Russell M. Genetic epidemiology of migraine and cluster-headache. Cephalalgia. 1997; 17: 683-701.

21. Ulrich V, Gervil M, Olesen J. The relative influence of environment and genes in episodic tension-type headache. Neurology 2004; 62: 2065-9.

22. Ulrich V, Russell MB, Jensen R, Olesen J. A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. Pain. 1996; 67: 501-06.

23. Aurora SK, Welch KMA. Brain hyperexcitability in migraine: evidence from transcranial magnetic stimulation studies. Current Opinion in Neurology. 1998; 11: 205-09.

24. Fabricius M, Fuhr S, Bhatia R et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006; 129: 778-90.

25. Hadjikhani N, Sanchez Del Rio M, Wu O et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98: 4687-92.

26. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Annals of Neurology. 1981; 9: 344-52.

27. Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nature Medicine. 1995; 1: 658-60.

28. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet. 1990; 336: 837-9.

29. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet. 1991; 338: 13-17.

30. Zwetsloot CP, Caekebe JF, Ferrari MD. Lack of asymmetry of middle artery blood flow velocity in unilateral migraine. Stroke. 1993; 24: 1335-8.

31. Iversen HK, Thomsen LL, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996; 16: 412-18.

32. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. European Journal of Neurology. 1994; 1: 73-80.

33. Olesen J, Iversen HK, Thomsen LL. Nitric oxide hypersensitivity. A possible molecular mechanisms of migraine pain. Neuroreport. 1993; 4: 1027-30.

34. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43: 242-6.

35. Buzzi MG, Carter WB, Shimizu T et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology. 1991; 30: 1193-200.

36. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes in human and cats. Annals of Neurology 1993; 33: 48-56.

37. Tvedskov JF, Lipka K, Ashina M et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Annals of Neurology. 2005; 58: 561-8.

38. Lassen LH, Haderslev PA, Jacobsen VB et al. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61.

39. Olesen J, Diener HC, Hustedt IW et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine. 2005; 350: 1104-10.

40. Mitsikostas DD, Thomas AM. Comorbidity of headache and depressive disorders. Cephalagia. 1999; 19: 211-17.

41. Holroyd KA, France JL, Nash JM, Hursey KG. Pain state as artefact in the psychological assessment of recurrent headache sufferers. Pain. 1993; 53: 229-35.

42. Janke EA, Holroyd KA, Romanek K. Depression increases onset of tension-type headache following laboratory stress. Pain. 2004; 111: 230-8.

43. Bendtsen L, Treede RD. Sensitization of myofascial pain pathways in tension-type headaches. In: Olesen J, Goadsby PJ, Ramadan N (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2005: 635-9.

44. Ashina S, Babenko L, Jensen R et al. Increased muscular and cutaneous pain sensitivity in cephalic region in patients with chronic tension-type headache. European Journal of Neurology. 2005; 12: 543-9.

45. Christensen M, Bendtsen L, Ashina M, Jensen R. Experimental induction of muscle tenderness and headache in tension-type headache patients. Cephalalgia. 2005; 25: 1061-7.

46. Ashina M, Stallknecht B, Bendtsen L et al. Tender points are not sites of ongoing inflammation - in vivo evidence in patients with chronic tension-type headache. Cephalalgia. 2003; 23: 109-16.

47. Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Current Pain and Headache Reports. 2005; 9: 415-22.

48. Ashina S, Bendtsen L, Ashina M et al. Evidence for generalized muscular and cutaneous hyperalgesia in patients with chronic tension-type headache. Cephalalgia. 2006; 26: 940-8.

49. Schmidt-Wilcke T, Leinisch E, Straube A et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005; 65: 1483-6.

50. Bendtsen L. Central sensitization in tension-type headache-possible pathophysiological mechanisms. Cephalalgia. 2000; 20: 486-508.

51. May A, Bahra A, Buchel C et al. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352: 275-8.

52. Wober-Bingol C, Wober C, Zeiler K et al. Tension headache and the cervical spine - plain X-ray findings. Cephalalgia. 1992; 12: 152-4.

53. Zwart JA. Neck mobility in different headache disorders. Headache. 1997; 37: 6-11.

54. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. Headache. 1998; 38: 10-17.

55. Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache centre. Neurology. 1998; 51: 245-9.

56. Skau M, Brennum J, Gjerris F, Jensen R. What is new about idiopatic intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia. 2006; 26: 384-99.

57. Rapoport A, Stann P, Gutterman DL et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache. 1996; 36: 14-19.

58. Schnieder P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia. 1996; 16: 481-5.

59. Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia. 2005; 25: 1159-67.

60. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: effect of a 2-month drug-free period. Neurology. 2006; 66: 1894-8.

61. Tfelt-Hansen P, Rolan P. Nonsteroidal antiinflammatory drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 449-57.

62. Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 469-503.

63. Mathew N, Tfelt-Hansen P. General and pharmacological approach to management of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 433-40.

64. Tfelt-Hansen P, Young WB, Silberstein SD. Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 505-13.

65. Tfelt-Hansen P, DeVries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-87.

66. Tfelt-Hansen P. A review of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia. 2006; 26: 1265-74.

67. Lainez MJ, Galvan J, Heras J, Vila C. Crossover, doubleblind clinical trial comparing almotriptan an ergotamine plus caffeine for acute migraine therapy. European Journal of Neurology. 2007; 14: 269-75.

68. Diener HC, Bussone G, de Liang H et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947-54.

69. Tfelt-Hansen P. Triptans vs. other classes of migraine medication. Cephalalgia. 2006; 26: 628.

70. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 459-67.

71. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine patients. British Journal of Clinical Pharmacology. 1983; 16: 695-9.

72. Tfelt-Hansen P, Saxena PR, Dahlof C et al. Ergotamine in the acute treatment of migraine - European Consensus. Brain. 2000; 123: 9-18.

73. Humphrey PP, Feniuk W, Perren MJ et al. The pharmacology of the novel 5-HT1-like agonist GR43175. Cephalalgia. 1989; 9: 23-33.

74. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994; 47: 622-51.

75. Ferrari MD, Saxena PR. Clinical and experimental effect of sumatriptan in humans. Trends in Pharmacological Sciences. 1993; 14: 129-33.

76. Ahn AH, Goadsby PJ. Animal models of headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 213-19.

77. Gomez-Mancilla B, Cutler NR, Leibowitz MT et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in migraine. Cephalalgia. 2001; 21: 727-32.

78. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine: a meta-analysis of 53 trials. Lancet. 2001; 358: 1668-75.

79. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-58.

80. Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. European Journal of Neurology. 2004; 11: 125-34.

81. Tfelt-Hansen P, Henry P, Mulder K et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995; 346: 923-6.

82. Diener HC, Bussone G, de Liano H et al. EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004; 24: 947-54.

83. Diener HC, Eikerman A, Gessner U et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. European Neurology. 2004; 52: 50-6.

84. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache. 2004; 44: 669-73.

85. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tables 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clinical Therapeutics. 2005; 27: 1785-94.

86. Carpay J, Schoenen J, Ahmad F et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clinical Therapeutics. 2004; 26: 214-23.

87. Gaist D, Andersen M, Aarup AL et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. British Journal of Clinical Pharmacology. 1997; 43: 429-33.

88. Gaist D, Tsiropoulos, Sindrup SH et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ. 1998; 316: 1352-3.

89. Diener HC, Silberstein SD. Medication overuse headaches. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams Ö Wilkins, 2006: 971-80.

90. Farkilä M, Olesen J, Dahlof C et al. Eletriptan for the treatment of migraine in patients with a previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003; 23: 463-71.

91. Mathew N, Schoenen J. Acute pharmacotherapy of tension-type headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 2000: 661-6.

92. Steiner TJ, Lange R, Voelker M. Aspirin in episodic tensiontype headache: a placebo-controlled dose-ranging comparison with paracetamol. Cephalagia. 2003; 23: 59-66.

93. Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of TTH. A double blind, placebo controlled study. Headache. 1987; 27: 90-5.

94. Dahlhöf CGH, Jacobs LD. Ketoprofen, paracetamol and placebo in the treatment of episodic tension-type headache. Cephalalgia. 1998; 16: 117-23.

95. Steiner TJ, Lange R. Ketoprofen (25 mg) in the symptomatic treatment of episodic tension-type headache: double blind placebo-controlled comparison with acetaminophen (1000 mg). Cephalalgia. 1998; 18: 38-43.

96. Van Gerven JMA, Schoemaker RC, Jacobs LD et al. Self-medication of a single episode of tension-type headache with ketoprofen, ibuprofen and placebo, home-monitored with an electronic patient diary. British Journal of Clinical Pharmacology. 1996; 42: 475-81.

97. Harden RN, Rogers D, Fink K, Gracely RH. Controlled trial of ketorolac in tension-type headache. Neurology. 1998; 50: 507-09.

98. Bove G, Nielsson N. Spinal manipulation in the treatment of episodic tension-type headache. A randomized controlled trial. JAMA. 1998; 280: 1576-9.

99. Evers S, Afra J, Frese A et al. (Members of the task force). EFNS guidelines on the drug treatment of migraine -report of an EFNS task force. European Journal of Neurology. 2006; 13: 560-72.

100. Silberstein SD, Tfelt-Hansen P. Antiepileptic drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Goadsby PJ et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 545-51.

101. Toda N, Tfelt-Hansen P. Calcium antagonists in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 539-44.

102. Tfelt-Hansen P, Rolan P. ß-Adrenoceptor blocking drugs in migraine prophylaxis. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 519-28.

103. Tfelt-Hansen P, Saxena PR. Antiserotonin drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Goadsby PJ et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 529-37.

104. Tfelt-Hansen P. Prioritizing prophylactic treatment of migraines. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 567-8.

105. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-9.

106. Mylecharane EJ, Tfelt-Hansen P. Nonsteroidal antiinflammatory and miscellaneous drugs in migraine prophylaxis. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds). The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 2000: 489-98.

107. Bendtsen L, Mathew N. Prophylactic pharmacotherapy of tension-type headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 735-42.

108. Bendtsen L, Jensen R, Olesen J. A nonselective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. Journal of Neurology, Neurosurgery, and Psychiatry. 1996; 61: 285-90.

109. Bendtsen L. Efficacy of antidepressants in headache prophylaxis. In: Olesen J, Silberstein P (eds). Preventive pharmacotherapy of headache disorders, 12th edn. New York: Oxford University Press, 2004: 103-11.

110. Cerbo R, Barbananti P, Fabbrini G et al. Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenic implications. Headache. 1998; 38: 453-7.

111. Oguzhanoglu A, Sahiner T, Kurt T, Akalin O. Use of amitriptyline and fluoxetine in the prophylaxis of migraine and tension-type headaches. Cephalalgia. 1999; 19: 531-2.

112. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment treatment of chronic tension-type headache. Neurology. 2004; 62: 1706-11.

113. Bendtsen L, Buchgreitz L Ashina S, Jensen R. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. European Journal of Neurology. 2007; 14: 187-93.

114. Hammill JM, Cook TM, Rosecrane JC. Effectiveness of a physical therapy regimen in the treatment of tension-type headache. Headache. 1996; 36: 149-53.

115. Jensen R, Olesen J. Is there an effect of physiotherapy in tension-type headache? Cephalalgia. 1995; 15: 152.

116. Torelli P, Jensen R, Olesen J. Physiotherapy for tensiontype headache: a controlled study. Cephalalgia. 2004; 24: 29-36.

117. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalalgia. 2006; 26: 769-71.

118. Silberstein SD, Gobel H, Jensen R et al. Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006; 26: 790-800.

119. Sandrini G, Ward TN. Acute treatment of cluster headaches. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 803-07.

120. van Vielt JA, Bahra A, Martin V et al. Intranasal sumatriptan in cluster headache: randomized, doubleblind placebo-controlled study. Neurology. 2003; 60: 630-3.

121. Cittadini E, May A, Straube A et al. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. Archives of Neurology. 2006; 63: 1537-42.

122. Leone M, Rapoport A. Preventive and surgical management of cluster headache. In: Olesen J, Goadsby PJ, Ramadan NM et al. (eds). The headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2006: 809-14.

123. Ambrosini A, Vandenheede M, Rossi P et al. Suboccipital injection with a mixture of rapid-and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain. 2005; 118: 92-6.

Think Clean and Green to Flawless Skin

Think Clean and Green to Flawless Skin

Lets accept the fact: many of us are skin conscious. As much as possible, we wanted to have a fresh, good looking skin. However, many of us failed to recognize that simple steps are the best ways to attain it.

Get My Free Ebook


Post a comment